Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 8Sarcoma 5Neoplasms 4Lymphoma, Non-Hodgkin 4Immunoproliferative Disorders 3Recurrence 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoproliferative Disorders 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Lymphoma 2Lymphatic Diseases 2Hematologic Diseases 2Sarcoma, Synovial 1Sarcoma, Endometrial Stromal 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms by Histologic Type 1Liposarcoma 1Leiomyosarcoma 1Immune System Diseases 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Fibrosarcoma 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Renal Cell 1Bone Neoplasms 1B-Cell Malignancies 1

Interventions

Pemetrexed 5ponatinib 4pembrolizumab 4Carboplatin 4Cisplatin 3130-nm albumin-bound paclitaxel 3tetulomab tetraxetan lu-177 2pralsetinib 2osimertinib 2napabucasin 2fludarabine 2ficlatuzumab 2entinostat 2durvalumab 2atezolizumab 2Rituximab 2Paclitaxel 2Lutetium 2Irinotecan 2Immunotherapy 2Imatinib Mesylate 2Gemcitabine 2Doxorubicin 2Dexamethasone 2Cyclophosphamide 2Bortezomib 2Bevacizumab 2vorasidenib 1siltuximab 1ruxolitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms by Histologic Type × Ifosfamide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡